MedTrace Logo

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

NCT01761565 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-10-01

Study results available
· View outcomes & findings →

Summary

Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs

Conditions

  • Plasma Concentrations

Interventions

DRUG

Single dose of SUF NT 15 mcg

DRUG

40 consecutive doses of SUF NT 15 mcg taken every 20 minutes

Sponsors & Collaborators

  • Talphera, Inc

    lead INDUSTRY

Principal Investigators

  • Sandra K. Willsie, D.O. · PRA

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761565 on ClinicalTrials.gov